A two-page resource providing simple explanations of how adherence is defined and measured in biomedical HIV prevention trials, with a focus on PrEP and microbicides.
Adherence in HIV Prevention Research: A primer for HIV prevention advocates
Intermittent PrEP (iPrEP) Research Agenda: Summary of an amfAR/AVAC think tank
A six-page summary of a meeting convened by amfAR and AVAC involving leaders from research and research sponsor agencies. The meeting reviewed the status of biomedical, behavioral and animal research relevant to intermittent PrEP, identifed gaps and priorities for moving forward.
Next steps for PrEP: Getting a proven prevention option to the people who need it
An article from the June 2013 edition of the GMHC newsletter discussing issues of PrEP introduction worldwide, reviewing efficacy trial results and current status of regulatory approval of Truvada as PrEP and rollout efforts.
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
Making Medical Male Circumcision Work for Women
A guide to VMMC for women. This report discusses the benefits male circumcision can have for women’s health as well as ways women can advocate and support the implementation of this HIV prevention method.
Viral Load Testing Delivers Systemic Benefits from the Individual to the Institution
This graphic from AVAC Report 2013 highlights the benefits of routine viral load testing for both individuals and institutions. Expanding access to viral load testing is a key step toward achieving virologic suppression.
The Global HIV Treatment U=U Gap: Existing people on ART versus people eligible under past and current WHO guidelines
This year WHO released eagerly anticipated comprehensive antiretroviral Treatment U=U (ART) guidelines addressing how to optimize ART for both Treatment U=U and prevention. The guidance recommends raising the CD4 threshold for Treatment U=U initiation to 500 CD4 cells or below — with priority given to people who are symptomatic or have CD4 cell counts at or below 350. As this graphic from AVAC Report 2013 illustrates, this shift in guidelines will increase the gap between the number of people eligible for ART worldwide and those currently receiving it.
2013 WHO ARV guidelines can decrease new infections and deaths
WHO 2013 guidelines recommend initiating ART in HIV positive people with CD4 cell counts of 500 or below. This graphic from AVAC Report 2013 illustrates how implementing these guidelines will reduce infections and save lives.